Integrated Upstream Platform -
From Cell Line to Manufacturing

Standard Disposables Design™ (SDD™)
(2017-07-20)

Buffer and media preparation are common in the production of antibody and proteinbased therapeutics, antibiotics, and vaccines. So the Standard Disposables Design™ (SDD™) initiative has been launched to concentrate on standardizing disposables for these applications. Read about PM Group’s vision to have most major biopharmaceutical companies store their media and buffers in the same design of disposable bags.

Raising the Bar for Upstream Processing
(2017-07-19)

Read this conversation with Stefan Schlack and Christel Fenge to learn about current market trends. Our experts summarize the key themes of our last European Upstream and Downstream Forum and talk about how our upstream solutions support customers, from concept to commercial production, to accelerate product development and scale-up.

Active Dashboard 2 Allows Easy Access to Process Performance Data
(2017-07-17)

We have launched the Active Dashboard 2, an advanced software solution. Delivering in-depth insights into process performance across the manufacturing network, the release helps managerial staff to achieve better timely decisions, ensuring superior manufacturing success. Read more about the benefits of the Active Dashboard 2 in our product news.

New Tools for Optimizing Custom Media Design
(2017-07-14)

At last year's European Upstream & Downstream Technology Forum, Michael Gillmeister presented independent case studies of a media optimization program offered jointly by Lonza and Sartorius Stedim Biotech. The program uses an ambr® 15 microbioreactor system to generate custom media that are chemically defined and contain no products of animal origin.

New Generation of Single-Use Bioreactors Can Reduce Bioprocess Development Time and Cost
(2017-07-11)

Our new BIOSTAT STR® bioreactor range featuring upgraded hardware and software, as well as a fully integrated, new design of Flexsafe STR® single-use bags, ensures quick and easy bioprocess scale-up of biologics and vaccines. Read the full SelectScience® article:

What Is the Best Way to Approach Biosimilar Development?
(2017-07-10)

To demonstrate biosimilarity it is essential that the biological product has been proven to be highly similar to the originator product and has no clinically meaningful differences in terms of its safety and efficacy. Read this blog entry to learn about the best practices for biosimilar development.

Virus Production Using Single-Use Bioreactors
(2017-07-07)

The veterinary pharmaceutical company HIPRA needed to rapidly expand the production capacity and faced the dilemma of installing more of the tried-and-tested stainless steel bioreactor capacity or opting instead for single-use bioreactors (with which HIPRA had no previous experience). The company decided to purchase single-use bioreactors from Sartorius Stedim Biotech. Read how HIPRA benefits from this decision.